AI assistant
Tempest Therapeutics, Inc. — Director's Dealing 2014
May 21, 2014
34632_dirs_2014-05-21_c0ec4397-e85e-455f-b3d7-2b9e6a8d7c5e.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: OvaScience, Inc. (OVAS)
CIK: 0001544227
Period of Report: 2014-05-19
Reporting Person: Dipp Michelle (Director, President and Chief Executive, 10% Owner)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2014-05-19 | Common Stock | P | 450 | $7.33 | Acquired | 817643 | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 3820571 | Indirect |
Footnotes
F1: The purchase reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan.
F2: Represents 769,566 shares of common stock and 48,077 RSUs.
F3: Longwood Fund GP, LLC is the general partner of Longwood Fund, LP. Voting and investment power with respect to the shares held by Longwood Fund, LP are vested in the Reporting Person, Richard Aldrich, and Christoph Westphal, M.D., Ph.D. (collectively, the "Managers"), the managers of Longwood Fund GP, LLC. Each of the Managers disclaims beneficial ownership of the shares held by Longwood Fund, LP, except to the extent of their respective pecuniary interest therein, and the inclusion of these shares in the report shall not be deemed an admission of beneficial ownership of the shares for purposes of Section 16 or for any other purpose.